Across TCGA pan-cancer cohorts, LINC01913 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LINC01913 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher LINC01913 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01913 expression acts as an unfavorable survival marker.

CESC, ESCA, and UCEC are the cancer types where LINC01913 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.095	0.875	<.001	42	view →
ESCA	OS	Median	II,III,IV	0.136	0.703	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LINC01913 tumor-vs-normal RNA expression · all LINC01913 data types